P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting 180 enrolled Poseida Therapeutics, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.

Timeline

Start: 2022-02-15
Primary completion: 2026-04
Completion: 2039-04

Publications

Gorodetska I, Samusieva A, Lahuta T, Ponomarova O, Socha O, Kozeretska I. Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research. Breast J. 2025 May 22;2025:9952727. doi: 10.1155/tbj/9952727. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	P-MUC1C-ALLO1	Cell therapy	—	Intravenous
Background	Rimiducid	Other / unclassified	—	—

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

Summary

Timeline

Publications

Drugs

Indications